 | • レポートコード：MRC22iR11006 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、254ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品 |
| Single User | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Five User | ￥880,452 (USD5,949) | ▷ お問い合わせ |
| Enterprise License | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に608.2億ドルであった世界の2型糖尿病治療薬市場規模が、2022年に657.5億ドルになり、2027年まで年平均8.38%で成長して986.2億ドルに達すると予測しています。本レポートでは、2型糖尿病治療薬の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場洞察、薬剤別（注射薬、経口薬）分析、用途別（心臓血管安全、血糖コントロール、低血糖回避）分析、流通チャネル別（病院薬局、オンライン薬局、小売薬局）分析、地域別（南北アメリカ、アジア太平洋、ヨーロッパ）分析、競争状況、企業情報などの項目を掲載しています。本書ではAbbott Laboratories、Amgen Inc.、AstraZeneca Plc.、Bayer AG、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Company、Chugai Pharmaceutical Co.、Daiichi Sankyo Co. Ltd、Eli Lilly and Co.、GlaxoSmithKline Plc.、Johnson & Johnson Services, Inc.、Merck & Co., Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場洞察 ・世界の2型糖尿病治療薬市場規模：薬剤別 - 注射薬の市場規模 - 経口薬の市場規模 ・世界の2型糖尿病治療薬市場規模：用途別 - 心臓血管安全用治療薬の市場規模 - 血糖コントロール用治療薬の市場規模 - 低血糖回避用治療薬の市場規模 ・世界の2型糖尿病治療薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の2型糖尿病治療薬市場規模：地域別 - 南北アメリカの2型糖尿病治療薬市場規模 - アジア太平洋の2型糖尿病治療薬市場規模 - ヨーロッパの2型糖尿病治療薬市場規模 ・競争状況 ・企業情報 |
The Global Type 2 Diabetes Drugs Market size was estimated at USD 60.82 billion in 2021 and expected to reach USD 65.75 billion in 2022, and is projected to grow at a CAGR 8.38% to reach USD 98.62 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Type 2 Diabetes Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug, the market was studied across Injectables and Oral. The Injectables is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral is further studied across Alpha-Glucosidase Inhibitors, Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide, Receptor Agonists, Secretagogues, Sodium Glucose Cotransport 2 Inhibitors, Sulfonylureas, and Thiazolidinediones.
Based on Application, the market was studied across Cardiovascular Safety, Glycemic Control, and Hypoglycemia Avoidance.
Based on Distribution, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Type 2 Diabetes Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 2 Diabetes Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 2 Diabetes Drugs Market, including Abbott Laboratories, Amgen Inc., AstraZeneca Plc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Daiichi Sankyo Co. Ltd, Eli Lilly and Co., GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk AS, Peptron, Pfizer Inc., Sanofi Aventis A/S, Sanofi SA, Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Co. Ltd.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Type 2 Diabetes Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 2 Diabetes Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 2 Diabetes Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Type 2 Diabetes Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Type 2 Diabetes Drugs Market?
6. What is the market share of the leading vendors in the Global Type 2 Diabetes Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Type 2 Diabetes Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Significance of diabetic prevalence globally
5.1.1.2. Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
5.1.1.3. Government initiatives and programs to create health awareness
5.1.2. Restraints
5.1.2.1. Products recall affecting brand reputation
5.1.3. Opportunities
5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
5.1.3.2. Rising investment in R&D and healthcare infrastructure development
5.1.4. Challenges
5.1.4.1. Stringent regulatory environment and time-consuming approval process
5.1.4.2. Lack of awareness among patients towards the availability of drugs
5.2. Cumulative Impact of COVID-19
6. Type 2 Diabetes Drugs Market, by Drug
6.1. Introduction
6.2. Injectables
6.3.1. Aspart
6.3.2. Exenatide
6.3.3. Glargine
6.3.4. Insulin
6.3.5. Leraglutide
6.3.6. Pramlintide
6.3. Oral
6.4.1. Alpha-Glucosidase Inhibitors
6.4.2. Biguanides
6.4.3. Dipeptidyl Peptidase-4 Inhibitors
6.4.4. Glucagon-Like Peptide
6.4.5. Receptor Agonists
6.4.6. Secretagogues
6.4.7. Sodium Glucose Cotransport 2 Inhibitors
6.4.8. Sulfonylureas
6.4.9. Thiazolidinediones
7. Type 2 Diabetes Drugs Market, by Application
7.1. Introduction
7.2. Cardiovascular Safety
7.3. Glycemic Control
7.4. Hypoglycemia Avoidance
8. Type 2 Diabetes Drugs Market, by Distribution
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Type 2 Diabetes Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Type 2 Diabetes Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Type 2 Diabetes Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Amgen Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AstraZeneca Plc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bayer AG
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Boehringer Ingelheim International GmbH
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bristol-Myers Squibb Company
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Chugai Pharmaceutical Co.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Daiichi Sankyo Co. Ltd
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Eli Lilly and Co.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. GlaxoSmithKline Plc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Johnson & Johnson Services, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Merck & Co., Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Novartis AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Novo Nordisk AS
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Peptron
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Pfizer Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Sanofi Aventis A/S
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sanofi SA
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sun Pharmaceutical Industries Limited
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Takeda Pharmaceutical Co. Ltd
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 2. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET DYNAMICS
FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2021 VS 2027 (%)
FIGURE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG, 2027
FIGURE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2027 (USD MILLION)
FIGURE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, 2018-2027 (USD MILLION)
FIGURE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, 2018-2027 (USD MILLION)
FIGURE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, 2018-2027 (USD MILLION)
FIGURE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2027 (USD MILLION)
FIGURE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, 2018-2027 (USD MILLION)
FIGURE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, 2018-2027 (USD MILLION)
FIGURE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2027 (USD MILLION)
FIGURE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2027 (USD MILLION)
FIGURE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DIPEPTIDYL PEPTIDASE-4 INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE, 2018-2027 (USD MILLION)
FIGURE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RECEPTOR AGONISTS, 2018-2027 (USD MILLION)
FIGURE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECRETAGOGUES, 2018-2027 (USD MILLION)
FIGURE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORT 2 INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2027 (USD MILLION)
FIGURE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2027 (USD MILLION)
FIGURE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CARDIOVASCULAR SAFETY, 2018-2027 (USD MILLION)
FIGURE 35. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYCEMIC CONTROL, 2018-2027 (USD MILLION)
FIGURE 36. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HYPOGLYCEMIA AVOIDANCE, 2018-2027 (USD MILLION)
FIGURE 37. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (%)
FIGURE 38. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (USD MILLION)
FIGURE 39. GLOBAL TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION, 2027
FIGURE 40. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 41. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 42. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 43. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 45. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 46. AMERICAS TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 47. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 51. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 52. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 53. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 54. UNITED STATES TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 55. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 56. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 57. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 58. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 59. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 60. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 61. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 62. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 63. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 65. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 66. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 67. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 68. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 69. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 70. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 71. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 72. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 73. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 74. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 75. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 76. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 77. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 78. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 79. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 80. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 81. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 82. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 83. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 84. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 85. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 86. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 87. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 88. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 89. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 90. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 91. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 92. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 93. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 94. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 95. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 96. GLOBAL TYPE 2 DIABETES DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 97. GLOBAL TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 98. GLOBAL TYPE 2 DIABETES DRUGS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021